Loading clinical trials...

Feasibility of Modulating Cognitive Control in OCD | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Feasibility of Modulating Cognitive Control in OCD

Evaluating Frontal Pole as a Window to Modulation of Cognitive Control in OCD

NCT07419009•Dartmouth-Hitchcock Medical Center

Summary

This study tests out procedures to look at whether a type of brain stimulation called transcranial magnetic stimulation impacts flexible shifts in behavior in obsessive-compulsive disorder (OCD). This study examines whether study procedures are feasible and acceptable to people participating in the study, but does not determine whether this type of brain stimulation causes changes.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Current primary DSM-5 OCD diagnosis and current Y-BOCS total score of ≥16 (OCD group, only) or no current diagnosis of an emotional disorder, and no known history of OCD, PTSD, anxiety disorder(s), or recurrent major depressive disorder (Healthy participant group, only)
•18-60 years of age
•ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent
•psychotherapy and/or psychiatric medication use remain stable for 6 weeks prior to study entry

Exclusion Criteria

•Presence of current psychiatric diagnosis (healthy control group, only)
•active substance use disorder
•history of mania or hypomania, or lifetime presence of significant psychotic symptoms
•active suicidal or homicidal ideation
•use of medications known to reduce seizure threshold (e.g., stimulants)
•organic brain disease or injury representing a contraindication to TMS
•any health problems that would interfere with safe and/or practical study participation, including contraindications to TMS (e.g., seizure disorder, presence of metal hardware that would come in close contact with the discharging coil)
•current pregnancy or planning to become pregnant during the study period

Key Dates

Start Date

February 15, 2026

Primary Completion Date

June 30, 2026

Completion Date

June 30, 2026

Last Updated

February 18, 2026

Enrollment

ESTIMATED participants

Conditions

Obsessive-Compulsive Disorder (OCD)

Interventions

continuous theta-burst transcranial magnetic stimulation (cTBS)

DEVICE

Acceptance and Commitment Therapy for Religious OCD

NCT06647589

Obsessive-Compulsive Disorder (OCD)

View study

COMPLETEDNA

Impact of EsTOCma on OCD Family Members

NCT06616350

Obsessive-Compulsive Disorder (OCD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions